Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...

Eli Lilly is experiencing explosive growth thanks ... According to data compiled by Coherent Market Insights, the global oncology drug market is expected to be worth $533 billion by 2031 ...

Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE ... On January 16, Mark Newton, Fundstrat Global head of technical strategy, joined ‘Squawk Box’ on CNBC to ...